Bahrain's NHRA approves Wegovy pills for treating obesity
The country's health regulator has cleared the oral version of Novo Nordisk's semaglutide for weight management.
peptides
-
Bahrain's NHRA approves Wegovy pills for treating obesity
-
Mochi Health moves to dose-based GLP-1 pricing and launches Mochi Labs bloodwork Mochi Health moves to dose-based GLP-1 pricing and launches Mochi Labs bloodwork
Compounded semaglutide and tirzepatide now cost less at lower starting doses, and members can order cholesterol, A1C and thyroid panels in the same app.
-
Mochi Health cuts compounded semaglutide and tirzepatide prices, adds lab testing Mochi Health cuts compounded semaglutide and tirzepatide prices, adds lab testing
Pricing now scales with dose, so people on lower starting doses pay less. The new Mochi Labs bloodwork service tracks A1C, cholesterol and thyroid, though not in NY, NJ, RI or HI.
-
Novo Nordisk will start selling its weight-loss drug Wegovy in vials Novo Nordisk will start selling its weight-loss drug Wegovy in vials
Novo Nordisk plans to offer Wegovy in vials as well as its usual format. The report gives no timing or pricing yet.
-
Polskie Radio reports US approval of Wegovy as a daily oral weight loss pill Polskie Radio reports US approval of Wegovy as a daily oral weight loss pill
Polskie Radio covers US regulators clearing the first daily oral version of Wegovy for weight loss. Details beyond that are thin.
-
Avon UK launches ANEW Peptides skincare with 2.5% peptides and 5% niacinamide 
Avon UK launches ANEW Peptides skincare with 2.5% peptides and 5% niacinamide
Avon pitches the new formula as a way to control shine while hydrating dry areas. It's a cosmetic skincare launch rather than a peptide drug.
-
R-Pharm launches Tirvella, a Russian tirzepatide, after Lilly's patent ran out 
R-Pharm launches Tirvella, a Russian tirzepatide, after Lilly's patent ran out
The once-weekly autoinjector is cleared for type 2 diabetes, overweight and obesity. Lilly never officially sold Mounjaro in Russia, and its rights there ended in November 2024.
-
Korea approves Hanmi's Eppe, its first homegrown GLP-1 obesity drug peptides typeshitPricesKorea approves Hanmi's Eppe, its first homegrown GLP-1 obesity drug
A first month is expected to cost about 129,800 won, roughly half of Mounjaro in Korea, while smuggling of cheaper Mounjaro from Japan has jumped 4.2 times.
-
Hanmi's Korean GLP-1 obesity drug launches at half Mounjaro's starting price 
peptides typeshitPricesHanmi's Korean GLP-1 obesity drug launches at half Mounjaro's starting price
South Korea's first homegrown obesity drug won approval, and Hanmi set its price to take on Wegovy and Mounjaro in the local market.
-
Silver Mirror launches the GLP-1 Volmira facial for skin changes during weight loss 
Silver Mirror launches the GLP-1 Volmira facial for skin changes during weight loss
The seven-step, needle-free facial costs $299 a visit or $239 a month at Silver Mirror's 10 studios. The company says it is not a medical procedure.
-
Hanmi's Eppe, Korea's first homegrown GLP-1 obesity drug, undercuts Mounjaro on price 
peptides typeshitPricesHanmi's Eppe, Korea's first homegrown GLP-1 obesity drug, undercuts Mounjaro on price
Industry sources put the first four weeks at about 129,800 won wholesale, roughly half of Mounjaro's starting cost. Launch is expected later this month.
-
Hanmi's Epe, Korea's first homegrown GLP-1 obesity drug, nears launch 
Hanmi's Epe, Korea's first homegrown GLP-1 obesity drug, nears launch
Approved on the 7th after a Phase 3 trial showing 9.75% average weight loss. Observers expect the lowest dose could cost around 100,000 won a month.
-
Ozari Health offers compounded semaglutide from $86 and tirzepatide from $125 a month Ozari Health offers compounded semaglutide from $86 and tirzepatide from $125 a month
Two new plans keep one price at every dose, with no membership fee. Prescriptions come from five named 503A pharmacies, and the cheaper plan skips California.
-
Ozari Health launches Ozari One, compounded tirzepatide at $125 a month at any dose Ozari Health launches Ozari One, compounded tirzepatide at $125 a month at any dose
The plan bills $375 per quarter with B12 included and ships everywhere but California. A pricier Ozari Select tier offers three formulations.